Synthesis and mannosidase inhibitory activity of 3-benzyloxymethyl analogs of swainsonine
โ Scribed by William H Pearson; Luyi Guo
- Publisher
- Elsevier Science
- Year
- 2001
- Tongue
- French
- Weight
- 98 KB
- Volume
- 42
- Category
- Article
- ISSN
- 0040-4039
No coin nor oath required. For personal study only.
โฆ Synopsis
Swainsonine (3), an inhibitor of Golgi a-mannosidase II, is a clinical candidate for cancer treatment. In order to avoid potential problems arising from its co-inhibition of lysosomal mannosidases, we have synthesized 3-benzyloxymethyl analogs of swainsonine (17 and 18). Initial screening of these new compounds is reported.
๐ SIMILAR VOLUMES
Swainsonine (1), an inhibitor of the important glycoprotein-processing enzyme Golgi a-mannosidase II, is a clinical candidate for cancer treatment. Analogs bearing substituents at C-6 and C-7 have been prepared and evaluated as inhibitors of a-mannosidase (jack bean), a closely related enzyme.
Swainsonine ( ) is an important mannosidase inhibitor that has been examined clinically as an anticancer drug. The preparation of analogs of swainsonine bearing a hydroxymethyl group at C(3), i.e., (3R)-3-(hydroxymethyl)swainsonine [( ), (3R)-HMS] and (3S)-3-(hydroxymethyl)swainsonine [( ), (3S)-HMS
Three deoxy derivatives 2-4 of the ฮฑ-mannosidase inhibitor mannostatin A (1) were synthesized, and their inhibition of Jack bean ฮฑ-mannosidase was evaluated in order to elucidate the roles of each of the three hydroxyl groups of the inhibitor. The 1-and 2-deoxy derivatives 2 and 3 retained some